Targeted cancer therapies are associated with cardiovascular toxicities such as decreased ejection fraction and atrial arrhythmias.
Agents targeting signaling pathways in cancer cells are less specific than advertised. A number of these agents induce cardiovascular toxic effects ranging from decreased ejection fraction to atrial arrhythmias.
Javid J. Moslehi (2016) studied this question.